Dronabinol Market Size

The Dronabinol market is projected to grow at a CAGR of 7.2% from 2025 to 2035, driven by the increasing acceptance of cannabinoid-based therapeutics and the expanding application of synthetic THC in managing chemotherapy-induced nausea and vomiting (CINV), anorexia in AIDS patients, and chronic pain conditions.

Dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), acts on the central nervous system by binding to CB1 receptors, producing appetite stimulation, antiemetic effects, and mild euphoria. It has gained regulatory approval in several countries for use in refractory CINV and AIDS-related anorexia and is also being explored in off-label uses for neuropathic pain, multiple sclerosis, and sleep disorders. The growing trend toward legalization and destigmatization of cannabis-related therapies is further boosting research investments and consumer interest in Dronabinol formulations.

Regionally, North America dominates the market, with the United States being the largest contributor due to early FDA approval, high prevalence of oncology and HIV/AIDS patients, and a growing openness to cannabinoid therapies in mainstream medicine.

The U.S. market also benefits from a robust pipeline of cannabinoid-based drug development and increasing insurance coverage for palliative care drugs. Canada follows closely due to its fully legalized cannabis environment, which supports both synthetic and natural cannabinoid markets.

In Europe, countries such as Germany, Italy, and the UK are gradually expanding access to Dronabinol for approved indications under medical cannabis programs, although reimbursement policies vary. Asia-Pacific is an emerging region, with Australia and Japan exploring clinical use and regulatory frameworks. In Latin America, Brazil and Mexico have approved some cannabinoid therapies, and Dronabinol adoption is expected to rise with improving legal clarity. The Middle East & Africa show minimal market penetration currently, but potential exists in South Africa and Israel due to ongoing medical cannabis initiatives.